Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19

COVID-19 Clinical Trial

Official title:

An Open Randomized Multicenter Comparative Study to Evaluate the Efficacy, Safety and Tolerability of the Use of Ambervin® for Intramuscular Administration and for Inhalation in Patients Hospitalized With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05656495
• Other study ID #: AMB-112021
• Status: Completed
• Phase: Phase 3
• Start date: February 28, 2022
• Est. completion date: November 22, 2022

Study information

• Verified date: April 2023
• Source: Promomed, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is open-labe randomized multicenter comparative Phase III study conducted in 8 medical facilities. The objective of the study is to assess the efficacy, safety and tolerability of Ambervin for intramuscular and inhaled administration in complex therapy COVID-19 compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19.

Description:

Upon signing the informed consent form and screening, 313 eligible patients hospitalized with COVID-19 were randomized at a 1:1:1 ratio to receive either Ambervin intramuscular 1mg 1 times a day for 10 days or Ambervin inhaled 10mg 1 times a day for 10 days or SOC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 313
• Est. completion date: November 22, 2022
• Est. primary completion date: November 22, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Availability of the Informed Consent Form of thePatient Information Leaflet (PIL) signed and dated bypatient.

2. Men and women aged 18 to 80 years inclusive at thetime of signing the Informed Consent Form in PIL.

3. Confirmed case of COVID-19 at the time ofscreening based on SARS-CoV-2 RNA test usingnucleic acid amplification (NAA) method. It isacceptable to include a patient with a presumptiveCOVID-19 diagnosis prior to receiving the results ofSARS-CoV-2 RNA test made at the screening stage.

4. Hospital admission due to COVID-19.

5. Moderate severity infection with SARS-CoV-2: Clinical signs (the presence of at least 2 of the following criteria):

• body temperature > 38 °C;

• RR > 22/min;

• CT pattern typical of a viral lesion

• shortness of breath on exertion;

• SpO2 < 95%;

• Serum CRP > 10 mg/L.

6. Lesion volume is minimal or moderate; CT 1-2.

7. Patient's consent to use reliable contraceptive methods through out the study and within 1 month for women and 3 months for men after its completion. Reliable means of contraception are: sexualabstinence, use of condom in combination withspermicide.

Women incapable of childbearing may also participate inthe study (with past history of:

hysterectomy, tubal ligation,infertility, menopause for more than 2 years), as well asmen with infertility or a history of vasectomy

Exclusion Criteria:

1. Hypersensitivity to components of the study drug.

2. Impossibility of CT procedure (for example, gypsumdressing or metal structures in the field of imaging).

3. Obstacles or inability to perform intramuscular injections and / or inhalations

4. Arterial hypotension (a decrease in blood pressure (BP) below 100/60 mm Hg) at the time of screening and / or a history of hypotensive crises.

5. The need for the use of drugs from the list of prohibited therapies.

6. Availability of criteria for severe and extremely severe disease at the time of screening

7. Presence within 6 months prior to screening of a probable or confirmed case of moderate COVID-19

8. History of presumptive or confirmed COVID-19 caseof moderate, severe and extremely severe course ofthe disease.

9. Vaccination less than 4 weeks prior to screening.

10. The need for treatment in the intensive care unit at the time of screening.

11. Impaired liver function (AST and/or ALT = 2 UNLand/or total bilirubin = 1.5 UNL) at the time ofscreening.

12. Renal impairment (GFR < 60 ml/min) at the time of screening.

13. Positive testing for HIV, syphilis, hepatitis B and/or C.

14. Chronic heart failure FC III-IV according to New York Heart Association (NYHA) functional classification.

15. Malignancies in the past medical history.

16. Alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening.

17. Epilepsy in history.

18. Schizophrenia, schizoaffective disorder, bipolardisorder, or other history of mental pathology orsuspicion of their presence at the time of screening.

19. Severe, decompensated or unstable somatic diseases (any disease or condition that threaten thepatient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study).

20. Any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study.

21. Patient's unwillingness or inability to comply with procedures of the Study Protocol (in the opinion of physician investigator).

22. Pregnant or nursing women or women planning pregnancy.

23. Participation in another clinical study for 3 monthsprior to inclusion in the study.

24. Other conditions that, according to the physicianinvestigator, prevent the patient from being includedin the study.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly
lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
• Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled
lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
• Standard of care
The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)

Locations

Country	Name	City	State
Russian Federation	Budgetary institution of the Chuvash Republic "Emergency Hospital"	Cheboksary
Russian Federation	City clinical Hospital ?24	Moscow
Russian Federation	Infectious Clinical Hospital No.1	Moscow
Russian Federation	State Budgetary Healthcare Institution City Clinical Hospital named after S. I. Spasokukotskiy of Moscow Healthcare Department	Moscow
Russian Federation	Regional Clinical Hospital	Ryazan
Russian Federation	Ryazan State Medical University named after academician I.P. Pavlov of Ministry of Health of the Russian Federation	Ryazan
Russian Federation	Ogarev Mordova State University of Ministry of Health of the Russian Federation	Saransk
Russian Federation	City Hospital No. 40 Kurortny District	Sestroretsk
Russian Federation	Regional State Budget Healthcare Institution "Clinical hospital No. 1"	Smolensk
Russian Federation	Voronezh Regional Clinical Hospital No.1	Voronezh

Sponsors (1)

Lead Sponsor	Collaborator
Promomed, LLC

Country where clinical trial is conducted

Russian Federation, 

References & Publications (1)

L.A. Balykova, O.A. Radaeva, K.Ya. Zaslavskaya, P.A. Bely, V.F. Pavelkina, N.A. Pyataev, A.Yu. Ivanova, G.V. Rodoman, N.E. Kostina, V.B. Filimonov, E.N. Simakina, D.A. Bystritsky, A.S. Agafina, K.N. Koryanova, D.Yu. Pushkar. Efficacy and safety of original drug based on hexapeptide succinate in complex COVID-19 therapy in adults hospitalized patients. Pharmacy & Pharmacology. 2022;10(6):573-588. DOI: 10.19163/2307-9266-2022-10-6-573-588

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of patients with category 0-1 as per categorical ordinal clinical improvement WHO scale	The proportion of patients with category 0-1 as per the categorical ordinal clinical improvement scale	From baseline to Visit 4 (days 14-15)
Secondary	Prevalence of patients with clinical status less than 4 points on the categorical ordinal WHO scale of clinical improvement	The proportion of patients with clinical status less than 4 points on the categorical ordinal WHO scale of clinical improvement	From baseline to Visit 3 (days 11-12) and 4 (days 14-15)
Secondary	Frequency of improvement in clinical status on a categorical ordinal WHO scale of clinical improvement of 2 or more categories	The proportion of patients with clinical status on a categorical ordinal WHO scale of clinical improvement of 2 or more categories	From baseline to Visit 3 (days 11-12) and 4 (days 14-15)
Secondary	Time to improve clinical status on a categorical ordinal scale of clinical improvement by = 1 point.	Number of days to improve clinical status on a categorical ordinal scale of clinical improvement by = 1 point.	From baseline to Visit 6 (study completion, day 28±1)
Secondary	Prevalence of patients eligible for discharge to continue outpatient treatment according to BMR	The proportion of patients eligible for discharge to continue outpatient treatment according to current Cuidelines	From baseline to Visit 2 (days 6-7), 3 (days 11-12)
Secondary	Prevalence of patients with RR < 22/min	The proportion of patients with RR < 22/min	From baseline to Visit 2 (days 6-7), 3 (days 11-12)
Secondary	Prevalence of patients with CRP level < 10 mg/l	The proportion of patients with CRP level < 10 mg/l	From baseline to Visit 2 (days 6-7), 3 (days 11-12)
Secondary	Prevalence of patients with blood lymphocytes > 1.2 x 10(9)/L	The proportion of patients with blood lymphocytes > 1.2 x 10(9)/L	From baseline to Visit 2 (days 6-7), 3 (days 11-12)
Secondary	Assessment of the degree of lung damage according to CT	The degree of lung damage according to CT	From baseline to Visit 4 (days 14-15)
Secondary	Prevalence of patients with SpO2 = 95% on 2 consecutive days	The proportion of patients with SpO2 = 95% on 2 consecutive days	From baseline to Visit 2 (days 6-7), 3 (days 11-12), 4 (days 14-15)
Secondary	The frequency of transfer of patients to the intensive care unit and intensive care	The proportion of patients transferred to the intensive care unit and intensive care	From baseline to Visit 6 (study completion, day 28±1)
Secondary	The frequency of cases of the use of high flow oxygen therapy, non-invasive and invasive ventilation of lung, ECMO	The proportion of patients who used high flow oxygen therapy, non-invasive and invasive ventilation of lung, ECMO	From baseline to Visit 6 (study completion, day 28±1)
Secondary	The frequency of cases of ARDS	The proportion of patients with ARDS	From baseline to Visit 6 (study completion, day 28±1)
Secondary	The frequency of patients with a fatal outcome	The proportion of patients with a fatal outcome	From baseline to Visit 6 (study completion, day 28±1)

External Links

•   Cyberleninka is an open access scientific electronic library